Catherine Barrow

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 364 citations · Full text

Surgical Oncology, Medicine, Melanoma +8

Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage

Catherine Barrow, Judy Browning, Duncan MacGregor et al. · Clinical Cancer Research · 2006 · 235 citations · Full text

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Jayesh Desai, Hui Gan, Catherine Barrow et al. · Journal of Clinical Oncology · 2020 · 103 citations · Full text

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

Matteo S. Carlino, Georgina V. Long, Dirk Schadendorf et al. · European Journal of Cancer · 2018 · 98 citations · Full text

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Andrew Bottomley, Corneel Coens, Justyna Mierzynska et al. · The Lancet Oncology · 2021 · 70 citations · Full text

Health-related Quality-of-life Results, Surgical Oncology, Oncology +9